SecBot SecBot
SECBOTREPLAY Home › Report › ONCY

ONCY · Oncolytics Biotech entered into a clinical supply agreement with…

Oncolytics Biotech, Inc. · PRESS-RELEASE filed Nov 11, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Nov 11, 2026 at 16:05 ET

Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate its investigational oncolytic virus immunotherapy, pelareorep, in combination with Coherus' PD-1 inhibitor LOQTORZI (toripalimab-tpzi) in a clinical study for patients with squamous cell anal carcinoma (SCAC) who have progressed on first-line therapy. The study is expected to begin in Q1 2027 at a U.S. cancer center, with Coherus supplying LOQTORZI. This is a non-financial collaboration that provides drug supply and supports a focused clinical evaluation in an indication with no approved second-line therapy.

  • Oncolytics entered a clinical supply agreement with Coherus Oncology for a study combining pelareorep and toripalimab in second-line SCAC patients.
  • The study is expected to begin in Q1 2027 at a premier U.S. cancer center.
  • No approved therapy exists for second-line SCAC patients.
  • Coherus will provide LOQTORZI (toripalimab-tpzi) to Oncolytics; no financial terms were disclosed.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access